If they can run a single Ph2 trial across all three indications, we have enough cash to go alone.
If successfull, and going on their track record, they should be, then we will quickly nail another deal of equal size and scope as FX/Retts deals.
I wrote deals because we should have 2 or 3 deals in place in next few weeks.
5 Orphan Drugs in development , would definitely set us up to be taken out for $Telephone Numbers.
It’s a riveting story.
Ann: New patent granted for Neuren's NNZ-2591 in Japan, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.48 |
Change
0.000(0.00%) |
Mkt cap ! $2.076B | |||
| Open | High | Low | Value | Volume |
| $16.48 | $16.77 | $16.28 | $3.108M | 188.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 105 | $16.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.54 | 885 | 2 |
View Market Depth
| Last trade - 16.13pm 28/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |